The upregulation of cyclin-dependent kinase 4 (CDK4) was also reported to mediate acquired resistance to dabrafenib combined trametinib in lung cancer patients with BRAF V600E mutation [313]. The gene discussed is BRAF; the disease is lung carcinoma.